Novel solutions to enable next-generation therapeutics
Optimer® therapeutics. Optimised for health.
Optimer® binders are increasingly
being investigated for use in all phases of drug discovery and development.
In a similar manner to antibody therapeutics, Optimer® binders can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
Aptamers are a proven modality in next-generation therapeutics with a number currently undergoing clinical trials and an aptamer therapeutic previously licensed for the treatment of macular degeneration.
Key benefits of Optimer® therapeutics:
- Rapid development: fully automated discovery accelerates the hit-to-lead phase
- Inert format: Optimer® binders are non-immunogenic and do not require humanisation
- Increased delivery to target site: Improved tissue penetration, blood-brain barrier permeability and the potential for higher dosing regimens due to small molecular weight
- Tailored specificity: biodistribution flexibility and reduced off-target effects for improved tolerability
- Intractable targets: interaction with epitopes on targets that are hidden or shielded from the much larger conventional antibodies and in vitro discovery for non-immunogenic or toxic targets
- Multimeric Optimer®: To create dual function therapeutics, improve binding kinetics, or improve therapeutic half-life
Download the whitepaper to find out how you could cut valuable years from discovery and development with Optimer.
Targeted delivery vehicles for future-ready therapeutics
Optimer® conjugates offer highly specific targeting vehicles for the delivery of therapeutic agents to specific cell populations and tissues for the treatment of disease.
The ability to identify Optimer® that discriminate between cell types, including organ-specific and healthy vs diseased cell populations, allows for site-specific therapeutic targeting and delivery.
Optimer® can be used to deliver a wide variety of cargo and toxic payloads, including:
- chemotherapeutic agents
- siRNA
- synthetic virions
- synthetic genes.
As the discovery library can be prepared with the drug and linker conjugate in place, we are able to develop for Optimer® binders with the drug in situ, to ensure optimal stability and performance of the end-stage therapeutic.
Key benefits of Optimer® conjugates
- High tumour uptake: small molecular size of Optimer® allows improved tissue penetration
- Optimised formatting and modification: site-specific functionalisation with a variety of linker types and excellent tox profile
- Security of supply: Synthetic production processes simplifies Optimer® drug conjugate development
- Inert format: Optimer® are non-immunogenic and do not require humanisation
- Selective cell/tissue targeting: biodistribution flexibility and reduced off-target effects
Download the whitepaper to find out how you could cut valuable years from discovery and development with Optimer.
Optimer® therapeutics are next-generation aptamers that are being applied to all stages of drug discovery and development. Optimer® can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease. Selected via our proprietary platforms for rapid generation and simple, consistent large-scale production, these novel therapeutics show potential to accelerate discovery and development for a wide range of human diseases.
We are working with commercial and academic partners to develop novel therapeutics for many intractable targets and to improve upon current treatments with the application of Optimer® technology.
